Gilva Therapeutics Co., Ltd.
No. 18, Siyuan St., Zhongzheng Dist., Taipei City 100047 ,
Taiwan (R.O.C.) (Room 909 of Complex for Research Excellence)
Registration No.：89114272
TEL：+886 2 33661914
FAX：+886 2 23652804
Long-Rong (Mark) Kao Ph.D.
Dr. Kao is a toxicologist who graduated from North Carolina State University. He subsequently held various research positions at the National Institutes of Health (NIH), Cornell University, Bayer, American Cyanamid, and Wyeth. Before retiring in 2020, he was the director of pharmaceutical development at Janssen Pharmaceutical, a division of Johnson and Johnson. Dr. Kao is a former president of the Taiwanese American Association of Biotechnology (TAAB). Currently, he is the Principal of Kao Preclinical Consulting Inc. and also serves as a consultant to several government agencies and private pharmaceutical companies in Taiwan.
Hsiu Ming Saunders Ph.D.
Dr. Hsiu Ming Saunders holds dual Ph.D.s in Pharmacokinetics and Toxicology from the University of Michigan. She is currently a U.S. patent attorney and has previously served as a U.S. patent examiner, specializing in drug patent lifecycle management, patent search and portfolio planning. She has extensive experience in filing U.S. patents in the fields of biotechnology, pharmaceuticals, and nanotechnology.
Chao-Wu (Stifen) Yu Ph.D.
Dr. Yu obtained his Ph.D. in Medicinal Chemistry from National Taiwan University. He has over 10 years of experience in new drug development in the industry, specializing in the design and synthesis of small molecule drugs and patent strategies. Prior to joining Gilva Pharmaceuticals, he worked at AnnJi Pharmaceuticals, where he served as the project leader for the design and development of HDAC6 inhibitor-related projects, resulting in multiple publications in international journals and patents. Dr. Yu is currently affiliated with the Department of Pharmacy at National Taiwan University.
Ajit D. Jagtap Ph.D.
Dr. Jagtap has more than 10 years of e experience in new drug discovery, CMC regulatory, formulation and analytical method development. He earned his Ph.D. at the National Taiwan University under the guidance of Prof. Ji-Wang Chern. This was followed by postdoctoral research at National Taiwan University and worked as a Senior Scientist at AnnJi Pharmaceuticals Co. Ltd., Taiwan with a primary focus of developing novel kinase, BACE1 and HDAC inhibitors. In October 2021, he joined as Post-Doctoral Associate at Center for Drug Design, College of Pharmacy, University of Minnesota.